HIGHLIGHTS
SUMMARY
Adenosine monophosphate-activated protein kinase (AMPK) acetyl-CoA carboxylase (ACC) signaling is activated in platelets by atherogenic lipids, particularly by oxidized low-density lipoproteins, through a CD36-dependent pathway. More interestingly, increased platelet AMPK-induced ACC phosphorylation is associated with the severity of coronary artery calcification as well as acute coronary events in coronary artery disease patients. Therefore, AMPK-induced ACC phosphorylation is a potential marker for risk stratification in suspected coronary artery disease patients. The inhibition of ACC resulting from its phosphorylation impacts platelet lipid content by down-regulating triglycerides, which in turn may affect platelet function. ACC is the first committed enzyme of the fatty acid biosynthesis pathway, while its phosphorylation on serine 79 by AMPK inhibits its activity (8) . We demonstrated that AMPK-ACC signaling is a key pathway in controlling platelet lipid content, thereby modulating platelet function and thrombus formation (9). However, ACC contribution to platelet lipid Here, we report platelet phosphoACC as a potential risk stratification marker in suspected CAD patients.
In consecutive patients admitted for coronary angiography, phosphoACC was significantly increased in circulating platelets of CAD patients and highly associated with acute coronary events. We identified an interplay between platelets and lipids, with oxLDL as a central contributor to increased platelet phosphoACC. Interestingly, the lipidomic data show that sustained phosphoACC regulates triglyceride (TG) lipids in circulating platelets of CAD patients.
METHODS
Methods (including experimental dataset) and reagents are described in the Supplemental Appendix. Kautbally et al.
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M u l t i d e t e c t o r
Values are mean AE SD, n (%), or median (interquartile range). *Pairwise significant difference (p < 0.05) between NS-CAD and NCAD. †Pairwise significant difference (p < 0.05) between ACS and NS-CAD. ‡Pairwise significant difference (p < 0.05) between ACS and N-CAD. §Pairwise significant difference (p < 0.05) between S-CAD and NCAD.
ACCTHEROMA ¼ prospective evaluation of Acetyl-CoA Carboxylase phosphorylation state in platelets as a marker of atherothrombotic coronary and extra-coronary artery disease; ACE ¼ angiotensinconverting enzyme; ACS ¼ acute coronary syndrome; ARB ¼ angiotensin receptor blocker; ASPI ¼ aspirin channel; AU ¼ arbitrary units; BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CRI ¼ chronic renal insufficiency; hsCRP ¼ high-sensitivity C-reactive protein; MI ¼ myocardial infarction; NCAD ¼ non-coronary artery disease; NS-CAD ¼ nonsignificant coronary artery disease; PCI ¼ percutaneous coronary intervention; S-CAD ¼ significant coronary artery disease; TG ¼ triglycerides; TRAP ¼ thrombin receptor activating peptide. Figure 1 . Table 1 ).
Kaplan-Meier event-free survival curves confirmed that patients with high phosphoACC levels (above 0.5 AU) had a higher events rate compared with low phosphoACC levels (log-rank test; p ¼ 0.036) (Figure 4) .
RELATIONSHIP BETWEEN PLATELET phosphoACC, CALCIFIED PLAQUE BURDEN, AND ThG MARKERS.
In patients who underwent MDCT, platelet phosphoACC, in addition to age and D-dimer levels, was independently associated to coronary calcification severity (global R 2 ¼ 0.47; p < 0.001) (Supplemental Table 2 ). Accordingly, as depicted in Figure 3E 
DISCUSSION
This study highlights that platelet phosphoACC is a risk marker in patients with suspected CAD and DAPT ¼ dual antiplatelet therapy; other abbreviations as in Tables 1 and 2 . PLATELET phosphoACC LEVELS AND RISK ASSESSMENT.
Despite the LDL cholesterol-lowering drugs and platelet inhibitors currently available, substantial Kautbally et al.
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Platelet ACC Phosphorylation in CAD Patients residual risk remains (18) , and many patients should be given more aggressive treatment (3, 19) . These patients must be identified by measurable risk markers.
Our study brings platelet phosphoACC to the fore as a marker for identifying high-risk patients. More importantly, higher phosphoACC states were detec- 
CONCLUSIONS
Our study identifies platelet phosphoACC as a risk stratification marker that reflects the interaction between proatherogenic lipids and circulating platelets.
In CAD patients, phosphoACC contributed to regulating endogenous lipid synthesis. We recently pro- It is tempting to speculate that increased phosphoACC is a counter-regulatory mechanism limiting lipogenesis and platelet reactivity in CAD patients within a proatherogenic environment.
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